NASDAQ:INMD - InMode Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $78.00
  • Forecasted Upside: -7.18 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$84.03
▲ +0.09 (0.11%)

This chart shows the closing price for INMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New InMode Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INMD

Analyst Price Target is $78.00
▼ -7.18% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for InMode in the last 3 months. The average price target is $78.00, with a high forecast of $103.00 and a low forecast of $42.00. The average price target represents a -7.18% upside from the last price of $84.03.

This chart shows the closing price for INMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in InMode. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2021Robert W. BairdBoost Price TargetOutperform$62.00 ➝ $80.00High
10/13/2021Canaccord GenuityBoost Price TargetBuy$60.00 ➝ $80.00High
10/13/2021BarclaysBoost Price TargetOverweight$60.00 ➝ $85.00High
10/12/2021Needham & Company LLCLower Price TargetBuy$103.00Low
7/29/2021Canaccord GenuityBoost Price TargetBuy$47.50 ➝ $60.00High
7/29/2021Needham & Company LLCBoost Price TargetBuy$59.50 ➝ $64.50High
7/13/2021BarclaysBoost Price TargetOverweight$46.00 ➝ $60.00Low
7/12/2021Needham & Company LLCBoost Price TargetBuy$47.00 ➝ $59.50Medium
5/24/2021BarclaysInitiated CoverageOverweight$46.00Medium
5/18/2021Needham & Company LLCInitiated CoverageBuy$47.00Medium
5/6/2021Canaccord GenuityBoost Price TargetBuy$40.00 ➝ $47.50High
5/6/2021Robert W. BairdBoost Price TargetOutperform$42.00 ➝ $52.00High
2/11/2021Robert W. BairdBoost Price TargetOutperform$29.00 ➝ $42.00Low
2/11/2021Canaccord GenuityBoost Price TargetBuy$34.50 ➝ $40.00Low
2/11/2021UBS GroupBoost Price TargetBuy$32.00 ➝ $42.00Low
10/21/2020Canaccord GenuityBoost Price TargetBuy$21.00 ➝ $25.50Medium
10/14/2020UBS GroupBoost Price TargetBuy$21.50 ➝ $23.50High
10/13/2020Robert W. BairdBoost Price TargetOutperform$21.50 ➝ $27.50High
8/17/2020BarclaysBoost Price TargetOverweight$18.00 ➝ $19.00High
5/7/2020Canaccord GenuityLower Price TargetBuy$25.00 ➝ $20.00Low
5/7/2020UBS GroupLower Price TargetBuy$23.00 ➝ $21.00Low
3/26/2020BarclaysLower Price TargetOverweight$24.00 ➝ $18.00Low
2/19/2020BarclaysBoost Price TargetOverweight$22.50 ➝ $24.00High
2/19/2020Canaccord GenuityReiterated RatingBuy$25.00High
1/28/2020Robert W. BairdReiterated RatingOutperform$22.50 ➝ $27.50Medium
11/6/2019BarclaysBoost Price TargetOverweight$13.50 ➝ $22.50High
11/6/2019Robert W. BairdReiterated RatingOutperform$13.50 ➝ $22.50High
9/3/2019BarclaysInitiated CoverageOverweight$13.50High
9/3/2019Robert W. BairdInitiated CoverageOutperform$13.50High
9/3/2019Canaccord GenuityInitiated CoverageBuy$15.00High
9/3/2019UBS GroupInitiated CoverageBuy$14.00High
(Data available from 10/22/2016 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2021
  • 3 very positive mentions
  • 23 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
7/24/2021
  • 2 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/23/2021
  • 9 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/22/2021
  • 12 very positive mentions
  • 38 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
10/22/2021

Current Sentiment

  • 12 very positive mentions
  • 38 positive mentions
  • 5 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

InMode logo
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Read More

Today's Range

Now: $84.03
Low: $82.29
High: $86.37

50 Day Range

MA: $70.54
Low: $52.51
High: $159.45

52 Week Range

Now: $84.03
Low: $18.02
High: $91.00

Volume

24,021 shs

Average Volume

2,920,097 shs

Market Capitalization

N/A

P/E Ratio

56.02

Dividend Yield

N/A

Beta

1.65

Frequently Asked Questions

What sell-side analysts currently cover shares of InMode?

The following Wall Street research analysts have issued stock ratings on InMode in the last year: Barclays PLC, Canaccord Genuity, Needham & Company LLC, Robert W. Baird, TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for INMD.

What is the current price target for InMode?

5 Wall Street analysts have set twelve-month price targets for InMode in the last year. Their average twelve-month price target is $78.00, suggesting a possible downside of 7.1%. Needham & Company LLC has the highest price target set, predicting INMD will reach $103.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $42.00 for InMode in the next year.
View the latest price targets for INMD.

What is the current consensus analyst rating for InMode?

InMode currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INMD will outperform the market and that investors should add to their positions of InMode.
View the latest ratings for INMD.

What other companies compete with InMode?

How do I contact InMode's investor relations team?

InMode's physical mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company's listed phone number is 972-4909-7470 and its investor relations email address is [email protected] The official website for InMode is www.inmodemd.com.